Copyright Reports & Markets. All rights reserved.

Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2019

Buy now

Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Overview

              Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Development

                Products under Development by Stage of Development

                  Products under Development by Therapy Area

                    Products under Development by Indication

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Therapeutics Assessment

                            Assessment by Mechanism of Action

                              Assessment by Route of Administration

                                Assessment by Molecule Type

                                  Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Companies Involved in Therapeutics Development

                                    Biomics Biotechnologies Co Ltd

                                      Bioneer Corp

                                        Boehringer Ingelheim GmbH

                                          Canget BioTekpharma LLC

                                            IMV Inc

                                              MimiVax LLC

                                                Optimum Therapeutics LLC

                                                  Oxford Vacmedix UK Ltd

                                                    Polyplus-Transfection SA

                                                      Stemline Therapeutics Inc

                                                        Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Drug Profiles

                                                          Antibody to Target Survivin for Oncology - Drug Profile

                                                            Product Description

                                                              Mechanism Of Action

                                                                R&D Progress

                                                                  Antisense RNAi Oligonucleotide to Inhibit Survivin and Bcl-2 for Bladder Cancer - Drug Profile

                                                                    Product Description

                                                                      Mechanism Of Action

                                                                        R&D Progress

                                                                          Antisense RNAi Oligonucleotide to Inhibit Survivin and Cyclin B1 for Oncology - Drug Profile

                                                                            Product Description

                                                                              Mechanism Of Action

                                                                                R&D Progress

                                                                                  Antisense RNAi Oligonucleotide to Inhibit Survivin for Solid Tumors - Drug Profile

                                                                                    Product Description

                                                                                      Mechanism Of Action

                                                                                        R&D Progress

                                                                                          Antisense RNAi Oligonucleotides to Inhibit Survivin for Pancreatic Cancer and Bladder Cancer - Drug Profile

                                                                                            Product Description

                                                                                              Mechanism Of Action

                                                                                                R&D Progress

                                                                                                  BGA-005 - Drug Profile

                                                                                                    Product Description

                                                                                                      Mechanism Of Action

                                                                                                        R&D Progress

                                                                                                          BI-1361849 - Drug Profile

                                                                                                            Product Description

                                                                                                              Mechanism Of Action

                                                                                                                R&D Progress

                                                                                                                  BKM-1644 - Drug Profile

                                                                                                                    Product Description

                                                                                                                      Mechanism Of Action

                                                                                                                        R&D Progress

                                                                                                                          BKM-1740 - Drug Profile

                                                                                                                            Product Description

                                                                                                                              Mechanism Of Action

                                                                                                                                R&D Progress

                                                                                                                                  DPX-Survivac - Drug Profile

                                                                                                                                    Product Description

                                                                                                                                      Mechanism Of Action

                                                                                                                                        R&D Progress

                                                                                                                                          FL-118 - Drug Profile

                                                                                                                                            Product Description

                                                                                                                                              Mechanism Of Action

                                                                                                                                                R&D Progress

                                                                                                                                                  MV-2C2 - Drug Profile

                                                                                                                                                    Product Description

                                                                                                                                                      Mechanism Of Action

                                                                                                                                                        R&D Progress

                                                                                                                                                          MX-106 - Drug Profile

                                                                                                                                                            Product Description

                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                R&D Progress

                                                                                                                                                                  OVM-200 - Drug Profile

                                                                                                                                                                    Product Description

                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                        R&D Progress

                                                                                                                                                                          SL-701 - Drug Profile

                                                                                                                                                                            Product Description

                                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                                R&D Progress

                                                                                                                                                                                  UC-112 - Drug Profile

                                                                                                                                                                                    Product Description

                                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                                        R&D Progress

                                                                                                                                                                                          Vaccine for Autoimmune Diseases, Glioblastoma Multiforme and Multiple Myeloma - Drug Profile

                                                                                                                                                                                            Product Description

                                                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                                                R&D Progress

                                                                                                                                                                                                  Vaccine for Colon Carcinoma and Lymphoma - Drug Profile

                                                                                                                                                                                                    Product Description

                                                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                                                        R&D Progress

                                                                                                                                                                                                          Vaccine for Oncology - Drug Profile

                                                                                                                                                                                                            Product Description

                                                                                                                                                                                                              Mechanism Of Action

                                                                                                                                                                                                                R&D Progress

                                                                                                                                                                                                                  Vaccine to Target BIRC5 for Relapsed Multiple Myeloma - Drug Profile

                                                                                                                                                                                                                    Product Description

                                                                                                                                                                                                                      Mechanism Of Action

                                                                                                                                                                                                                        R&D Progress

                                                                                                                                                                                                                          Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Dormant Products

                                                                                                                                                                                                                            Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Discontinued Products

                                                                                                                                                                                                                              Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Product Development Milestones

                                                                                                                                                                                                                                Featured News & Press Releases

                                                                                                                                                                                                                                  Jan 29, 2019: IMV announces clinical update for DPX-Survivac program in ovarian cancer following positive feedback from U.S. FDA

                                                                                                                                                                                                                                    Dec 13, 2018: IMV presents updated positive data from phase 1b/2 combination clinical trial in advanced ovarian cancer at 2018 ESMO Immuno-Oncology Congress

                                                                                                                                                                                                                                      Dec 10, 2018: IMV Announces Updated Clinical Data Presentation for Lead Candidate DPX-Survivac's Phase 1b/2 Immunotherapy Combination Trial at the ESMO Immuno-Oncology Congress 2018

                                                                                                                                                                                                                                        Nov 28, 2018: Brain Cancer Immunotherapy SurVaxM extends survival, even in hard-to-treat patients

                                                                                                                                                                                                                                          Nov 22, 2018: IMV amends Phase Ib/II trial of recurrent ovarian cancer drug

                                                                                                                                                                                                                                            Nov 16, 2018: Stemline Therapeutics announces oral presentation of SL-701 phase 2 data in second-line Glioblastoma at the 23rd Annual Meeting of the Society of Neuro-Oncology (SNO)

                                                                                                                                                                                                                                              Oct 16, 2018: Stemline Therapeutics announces SL-701 clinical data to be featured, including an Oral Presentation, at upcoming ESMO 2018 Congress

                                                                                                                                                                                                                                                Sep 18, 2018: IMV announces early positive results from phase 2 clinical trial of lead candidate DPX-Survivac in combination with Merck’s Keytruda in patients with DLBCL

                                                                                                                                                                                                                                                  Sep 11, 2018: IMV announces phase 2 basket trial in collaboration with Merck to evaluate DPX-Survivac in combination with KEYTRUDA across five solid tumor indications

                                                                                                                                                                                                                                                    Aug 09, 2018: IMV reaches multiple milestones in advanced ovarian cancer clinical trial

                                                                                                                                                                                                                                                      Jun 13, 2018: Immunotherapy Vaccine Shows Great Promise in Treating Brain Cancer Patients

                                                                                                                                                                                                                                                        Jun 05, 2018: Stemline Therapeutics Announces Positive Data Presentations on SL-701 at ASCO

                                                                                                                                                                                                                                                          Jun 03, 2018: IMV Presents New Positive Data From Phase 1b/2 Combination Clinical Trial in Advanced Ovarian Cancer at 2018 ASCO Meeting

                                                                                                                                                                                                                                                            May 29, 2018: Interim Results from Clinical Trial of Immunotherapy for Glioblastoma Show Significant Clinical Benefit

                                                                                                                                                                                                                                                              May 21, 2018: MimiVax Announces Positive Interim Results from Phase II Trial of SurVaxM Immunotherapy for the Treatment of Newly Diagnosed Glioblastoma

                                                                                                                                                                                                                                                                Appendix

                                                                                                                                                                                                                                                                  Methodology

                                                                                                                                                                                                                                                                    Coverage

                                                                                                                                                                                                                                                                      Secondary Research

                                                                                                                                                                                                                                                                        Primary Research

                                                                                                                                                                                                                                                                          Expert Panel Validation

                                                                                                                                                                                                                                                                            Contact Us

                                                                                                                                                                                                                                                                              Disclaimer

                                                                                                                                                                                                                                                                              Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Pipeline Review, H1 2019

                                                                                                                                                                                                                                                                              Summary

                                                                                                                                                                                                                                                                              Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) - Baculoviral inhibitor of apoptosis repeat-containing 5 or BIRC5 also known as Survivin is a protein encoded by the BIRC5 gene. It has dual roles in promoting cell proliferation and preventing apoptosis. It acts as an important regulator of the localization of this complex directs CPC movement to different locations from the inner centromere during prometaphase to midbody during cytokinesis and participates in the organization of the center spindle by associating with polymerized microtubules. The complex with RAN plays a role in mitotic spindle formation by serving as a physical scaffold to help deliver the RAN effector molecule TPX2 to microtubules. It counteracts a default induction of apoptosis in G2/M phase. It plays a role in neoplasia.

                                                                                                                                                                                                                                                                              Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) pipeline Target constitutes close to 20 molecules. Out of which approximately 15 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Preclinical and Discovery stages are 4, 9 and 2 respectively. Similarly, the universities portfolio in Phase II and Preclinical stages comprises 1 and 4 molecules, respectively. Report covers products from therapy areas Oncology and Immunology which include indications Bladder Cancer, Melanoma, Prostate Cancer, Autoimmune Disorders, Bone Metastasis, Glioblastoma Multiforme (GBM), Non-Small Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Solid Tumor, Colon Carcinoma, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Fallopian Tube Cancer, Head And Neck Cancer, Hepatocellular Carcinoma, Lymphoma, Malignant Mesothelioma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Lung Cancer, Multiple Myeloma (Kahler Disease), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Peritoneal Cancer, Recurrent Glioblastoma Multiforme (GBM) and Relapsed Multiple Myeloma.

                                                                                                                                                                                                                                                                              The latest report Baculoviral IAP Repeat Containing Protein 5 - Pipeline Review, H1 2019, outlays comprehensive information on the Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics development with respective active and dormant or discontinued projects.

                                                                                                                                                                                                                                                                              The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

                                                                                                                                                                                                                                                                              Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

                                                                                                                                                                                                                                                                              Scope

                                                                                                                                                                                                                                                                              - The report provides a snapshot of the global therapeutic landscape for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
                                                                                                                                                                                                                                                                              - The report reviews Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
                                                                                                                                                                                                                                                                              - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
                                                                                                                                                                                                                                                                              - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
                                                                                                                                                                                                                                                                              - The report reviews key players involved in Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics and enlists all their major and minor projects
                                                                                                                                                                                                                                                                              - The report assesses Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
                                                                                                                                                                                                                                                                              - The report summarizes all the dormant and discontinued pipeline projects
                                                                                                                                                                                                                                                                              - The report reviews latest news and deals related to Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) targeted therapeutics

                                                                                                                                                                                                                                                                              Reasons to buy

                                                                                                                                                                                                                                                                              - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
                                                                                                                                                                                                                                                                              - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
                                                                                                                                                                                                                                                                              - Identify and understand the targeted therapy areas and indications for Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5)
                                                                                                                                                                                                                                                                              - Identify the use of drugs for target identification and drug repurposing
                                                                                                                                                                                                                                                                              - Identify potential new clients or partners in the target demographic
                                                                                                                                                                                                                                                                              - Develop strategic initiatives by understanding the focus areas of leading companies
                                                                                                                                                                                                                                                                              - Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
                                                                                                                                                                                                                                                                              - Devise corrective measures for pipeline projects by understanding Baculoviral IAP Repeat Containing Protein 5 (Apoptosis Inhibitor 4 or Apoptosis Inhibitor Survivin or BIRC5) development landscape
                                                                                                                                                                                                                                                                              - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

                                                                                                                                                                                                                                                                              Buy now